Abstract：
The favorable effects of probiotics have been demonstrated in allergic disorders. However, the underlying immunological mechanisms are poorly understood. In the present study, we investigated the improvement of clinical symptoms and immunological balance after receiving probiotics in patients with asthma.
The present study was a randomized, double-blind, placebo-controlled trial in which 40 patients with asthma were enrolled. They were treated with probiotics or placebo: 1 capsule/day for 8 weeks. Pulmonary function test, percentage of CD4+ CD25+ FoxP3+ Tregs, and gene expression of T-bet, GATA-3, RORγt, and Foxp3 in PBMCs were assessed at baseline and after treatment.
Our results showed a significant increase in the expression of FoxP3 and CD4+ CD25+ FoxP3+ Tregs population, while RORγt and GATA3 expression were reduced. In addition, pulmonary function tests showed a significant improvement in forced expiratory volume and forced vital capacity after receiving probiotics.
Our findings demonstrate that 8-week treatment with probiotic supplementation can control T-helper 2-predominant and Th17 pro-inflammatory responses and improve forced vital and forced expiratory volume in asthmatic patients. It seems probiotics can be used besides common treatments for patients with asthma.
The present study was a randomized, double-blind, placebo-controlled trial in which 40 patients with asthma were enrolled. They were treated with probiotics or placebo: 1 capsule/day for 8 weeks. Pulmonary function test, percentage of CD4+ CD25+ FoxP3+ Tregs, and gene expression of T-bet, GATA-3, RORγt, and Foxp3 in PBMCs were assessed at baseline and after treatment.
Our results showed a significant increase in the expression of FoxP3 and CD4+ CD25+ FoxP3+ Tregs population, while RORγt and GATA3 expression were reduced. In addition, pulmonary function tests showed a significant improvement in forced expiratory volume and forced vital capacity after receiving probiotics.
Our findings demonstrate that 8-week treatment with probiotic supplementation can control T-helper 2-predominant and Th17 pro-inflammatory responses and improve forced vital and forced expiratory volume in asthmatic patients. It seems probiotics can be used besides common treatments for patients with asthma.
摘要：
背景：已证明益生菌在过敏性疾病中的有利作用。然而,潜在的免疫学机制知之甚少。在本研究中,我们调查了哮喘患者接受益生菌后临床症状和免疫平衡的改善情况。
方法：本研究是一项随机，双盲,纳入40例哮喘患者的安慰剂对照试验.他们用益生菌或安慰剂治疗:1粒/天,持续8周。肺功能检查,CD4+CD25+FoxP3+Tregs的百分比，和T-bet的基因表达，GATA-3,RORγt,在基线和治疗后评估PBMC中的Foxp3。
结果：我们的结果显示FoxP3和CD4+CD25+FoxP3+Tregs群体的表达显著增加，RORγt和GATA3表达降低。此外,肺功能试验显示,接受益生菌后用力呼气量和用力肺活量显著改善.
结论：我们的研究结果表明，8周的益生菌补充剂治疗可以控制T辅助细胞2型和Th17型促炎反应，并改善哮喘患者的用力肺活量和用力呼气量。似乎益生菌除了用于哮喘患者的常规治疗之外还可以使用。
方法：本研究是一项随机，双盲,纳入40例哮喘患者的安慰剂对照试验.他们用益生菌或安慰剂治疗:1粒/天,持续8周。肺功能检查,CD4+CD25+FoxP3+Tregs的百分比，和T-bet的基因表达，GATA-3,RORγt,在基线和治疗后评估PBMC中的Foxp3。
结果：我们的结果显示FoxP3和CD4+CD25+FoxP3+Tregs群体的表达显著增加，RORγt和GATA3表达降低。此外,肺功能试验显示,接受益生菌后用力呼气量和用力肺活量显著改善.
结论：我们的研究结果表明，8周的益生菌补充剂治疗可以控制T辅助细胞2型和Th17型促炎反应，并改善哮喘患者的用力肺活量和用力呼气量。似乎益生菌除了用于哮喘患者的常规治疗之外还可以使用。
